SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

BioMarin Fabry Drug License Leads Quiet Week in Biotech Dealmaking

U.S.-listed drugmakers favored asset licensing and bankruptcy purchases of drug candidates over large company acquisitions this week, in a quieter stretch than earlier in 2026.

BMRNTEVA

Related stories